Eli Lilly | LLY - Equity Capital And Reserves


Eli Lilly reported $31.2B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -6.66B 3.39B Mar/2026
Abbott USD 52.06B 69M Mar/2026
ALKERMES USD 1.75B 67.76M Mar/2026
Amgen USD 9.19B 532M Mar/2026
AstraZeneca USD 47.33B 1.33B Mar/2026
Baxter International USD 6.04B 86M Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Coherus Biosciences USD 61.01M 26.76M Dec/2025
Drreddys Laboratories INR 4.14B 107.72M Dec/2025
Eli Lilly USD 31.2B 4.66B Mar/2026
Gilead Sciences USD 23.52B 897M Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Glaxosmithkline GBP 22.06B 360M Dec/2025
J&J USD 81.19B 358M Mar/2026
Medtronic USD 48.99B 128M Dec/2025
Merck USD 45.88B 6.73B Mar/2026
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Novartis USD 46.13B 1.8B Dec/2025
Novo Nordisk DKK 203.07B 9.02B Mar/2026
Perrigo USD 2.5B 436.7M Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Phibro Animal Health USD 361.83M 29.47M Mar/2026
Prestige Brands USD 1.89B 58.06M Mar/2026
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Sanofi EUR 72.81B 1.1B Mar/2026
Sanofi EUR 71.71B 14.25B Dec/2025
United Therapeutics USD 5.9B 1.2B Mar/2026
Zoetis USD 3.23B 98M Mar/2026